Company news
Nuvalent, Inc. (NASDAQ:NUVL) news
Nuvalent, Inc. news releases on 6ix. Latest, Jul 13, 2022: Nuvalent to Present New NVL-655 Preclinical Data and ARROS-1 Trial in Progress Poster for NVL-520…
Press releases — page 3
Nuvalent to Present New NVL-655 Preclinical Data and ARROS-1 Trial in Progress Poster for NVL-520 at IASLC 2022 World Conference on Lung Cancer Annual Meeting
July 12, 2022
Nuvalent Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers
June 20, 2022
Nuvalent to Present at the 2022 Jefferies Healthcare Conference
June 1, 2022
Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results
May 11, 2022
Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022
April 7, 2022
Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference
April 6, 2022
Nuvalent Appoints Anna Protopapas as Chair of Board of Directors
March 30, 2022
Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
March 28, 2022
Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022
March 7, 2022
Nuvalent to Participate in the Cowen 42nd Annual Healthcare Conference
March 1, 2022
Nuvalent Appoints Emily Drabant Conley, PhD, to Board of Directors
February 2, 2022
Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor
January 6, 2022
Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022
Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results
November 9, 2021
New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC
October 6, 2021
Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
September 7, 2021
Nuvalent Announces Closing of Upsized Initial Public Offering
August 1, 2021